Literature DB >> 20084227

Therapy of suspected bacterial meningitis in Canadian children six weeks of age and older.

.   

Abstract

Entities:  

Year:  2001        PMID: 20084227      PMCID: PMC2804530          DOI: 10.1093/pch/6.3.147

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  29 in total

1.  Invasive Haemophilus influenzae serotype B surveillance in Ontario--documenting the progression towards elimination.

Authors:  J Sciberras
Journal:  Can Commun Dis Rep       Date:  1999-11-01

2.  Recurrent penicillin-resistant pneumococcal meningitis after chloramphenicol therapy.

Authors:  I R Friedland; K P Klugman
Journal:  Pediatr Infect Dis J       Date:  1991-09       Impact factor: 2.129

3.  Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988.

Authors:  P B McIntyre; C S Berkey; S M King; U B Schaad; T Kilpi; G Y Kanra; C M Perez
Journal:  JAMA       Date:  1997-09-17       Impact factor: 56.272

4.  Alteration of cerebrospinal fluid findings by partial treatment of bacterial meningitis.

Authors:  G M Converse; J M Gwaltney; D A Strassburg; J O Hendley
Journal:  J Pediatr       Date:  1973-08       Impact factor: 4.406

Review 5.  Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae.

Authors:  M M París; O Ramilo; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

6.  Slow recovery of cerebrospinal fluid glucose and protein concentrations distinguish pneumococcal from Haemophilus influenzae and meningococcal meningitis in children.

Authors:  I Roine; L M Foncea; W Ledermann; H Peltola
Journal:  Pediatr Infect Dis J       Date:  1995-10       Impact factor: 2.129

7.  Evidence-based medicine.

Authors:  D W MacPherson
Journal:  Can Commun Dis Rep       Date:  1994-09-15

8.  In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  Neisseria meningitidis with decreased susceptibility to penicillin in Saskatchewan, Canada.

Authors:  J M Blondeau; F E Ashton; M Isaacson; Y Yaschuck; C Anderson; G Ducasse
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

10.  Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.

Authors:  T Q Tan; G E Schutze; E O Mason; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more
  6 in total

1.  Steroids in meningitis Part B: Clinical commentary.

Authors:  Wendy Vaudry
Journal:  Paediatr Child Health       Date:  2006-01       Impact factor: 2.253

2.  Management of bacterial meningitis in children: Controversies in the management of bacterial meningitis.

Authors:  James D Kellner
Journal:  Paediatr Child Health       Date:  2002-09       Impact factor: 2.253

3.  Pneumococcal vaccine for children.

Authors: 
Journal:  Paediatr Child Health       Date:  2002-07       Impact factor: 2.253

4.  Corticosteroids for suspected bacterial meningitis in children - Status in 2005.

Authors:  James D Kellner
Journal:  Paediatr Child Health       Date:  2005-02       Impact factor: 2.253

5.  Antibiotic choices by paediatric residents and recently graduated paediatricians for typical infectious disease problems in children.

Authors:  Katharine Smart; Jean-Francois Lemay; James D Kellner
Journal:  Paediatr Child Health       Date:  2006-12       Impact factor: 2.253

6.  Dexamethasone and antibiotics for the empirical treatment of bacterial meningitis in Canadian children: A survey of paediatric infectious diseases specialists.

Authors:  Bjk Tan; Hd Davies
Journal:  Paediatr Child Health       Date:  2002-07       Impact factor: 2.253

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.